NovoCure Limited (NVCR) Q1 2026 Earnings Call

Investor webinar replay

Meeting Overview The NOVA Q1 2026 earnings call focused on the company's financial performance and updates on various cancer treatment programs, particularly the launch of OptunePax for pancreatic cancer. The executives discussed growth metrics, product developments, and upcoming clinical trials, highlighting a promising start to the year. Key Discussion Points - Overview of Q1 2026 financial performance, including double-digit growth in active patients and net revenues. - Launch of OptunePax for pancreatic cancer, including FDA approval and initial adoption metrics. - Positive feedback from physicians regarding the PANOVA3 data and the importance of outcomes in pancreatic cancer treatment. - Update on the GBM (glioblastoma) and lung cancer programs, including the upcoming Trident trial. - Product development initiatives aimed at improving patient and prescriber experience with TT fields therapy. - Presentation of promising data from the PANOVA4 trial and ongoing research into RAS i...

Watch the replay

Replay transcript excerpt

[Speaker identities could not be resolved; generic labels used] [00:00] Speaker 1: Good day and thank you for standing by. Welcome to the NOVA Q1 2026 [00:04] Speaker 1: earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your 1st speaker today, Adam Dainey. Please go ahead. [00:34] Speaker 2: Good morning, and thank you for joining us to review Novocure's 1st 0.25 of 2026 financial performance. [00:39] Speaker 2: I'm joined on the phone today with our Executive Chairman, Bill Doyle, [00:43] Speaker 2: CEO, Frank Leonard, Chief Innovation and Medical Officer, Ori Weinberg, and CFO, Christoph Brockman. [00:48] Speaker 2: Other members of our executive leadership team will be available for Q&A. [00:53] Speaker 2: For your reference, slides accompanying this earnings release can be found on our website, Novacure.com, [00:59] Speaker 2: on the investor relations page under quarterly reports. [01:02] Speaker 2: Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements and actual results could differ materially from those projected in these statements. [01:13] Speaker 2: These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. [01:20] Speaker 2: We do not intend to update publicly an...